Hospital
The Charlotte-Mecklenburg Hospital Authority
The Charlotte-Mecklenburg Hospital Authority was paid $9.77M by Medicaid between Jan 2019 and Dec 2024, across 81 billing codes. Its largest line is 99283, emergency room visit (moderate) — 44% of everything it billed.
33Billing provider infoTHE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY
WADESBORO, NC 28170
WADESBORO, NC 28170
33aNPI1659856060assigned 10/02/2018
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.77M
24GClaims125,515
24DCodes billed81
24AFirst – last monthJan 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#50 of 92
Median peer was paid$11.47M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DEFURIO, ANTHONY controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 24,674 | $1.14M | |
| 2020 | 18,792 | $1.03M | |
| 2021 | 19,522 | $1.41M | |
| 2022 | 19,379 | $1.89M | |
| 2023 | 22,825 | $2.23M | |
| 2024incomplete | 20,323 | $2.07M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 44% | 14,330 | 13,206 | $4.31M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 31% | 11,248 | 10,379 | $3.03M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 4,438 | 4,104 | $982K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.6% | 2,465 | 2,245 | $350K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.9% | 12,779 | 11,322 | $183K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 3,380 | 3,089 | $125K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 1,502 | 1,342 | $121K |
| 80053 | Comprehensive metabolic panel | <1% | 11,353 | 10,470 | $86K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,028 | 10,989 | $80K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,953 | 2,773 | $60K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 844 | 768 | $56K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,558 | 1,437 | $47K |
69 more codes
| J3490 | Unclassified drugs | <1% | 11,041 | $35K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,082 | $29K |
| Q3014 | Telehealth originating site facility fee | <1% | 1,965 | $26K |
| 80061 | Lipid panel | <1% | 2,238 | $24K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,432 | $19K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,236 | $17K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 397 | $15K |
| 84484 | <1% | 1,877 | $13K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 182 | $10K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 25 | $10K |
| 81025 | <1% | 1,262 | $10K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 461 | $10K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 55 | $8K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,280 | $8K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 36 | $7K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,243 | $7K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 5,099 | $7K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 136 | $5K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 799 | $5K |
| G0378 | Hospital observation service, per hour | <1% | 26 | $5K |
| 81001 | <1% | 1,488 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 363 | $4K |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,223 | $4K |
| 85027 | <1% | 984 | $4K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 619 | $4K |
| 87430 | <1% | 245 | $4K | |
| 83735 | <1% | 736 | $4K | |
| 84466 | <1% | 348 | $3K | |
| 82728 | <1% | 310 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,326 | $3K |
| 96127 | <1% | 1,535 | $3K | |
| 83690 | <1% | 407 | $3K | |
| 87070 | <1% | 171 | $2K | |
| 80050 | General health panel | <1% | 47 | $2K |
| 82607 | <1% | 172 | $2K | |
| 83540 | <1% | 348 | $2K | |
| 85610 | <1% | 483 | $1K | |
| 87486 | <1% | 36 | $1K | |
| 87581 | <1% | 36 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 200 | $933.29 |
| 81003 | <1% | 398 | $895.86 | |
| 84481 | <1% | 65 | $875.04 | |
| 82803 | <1% | 40 | $687.19 | |
| 83880 | <1% | 27 | $672.92 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 37 | $647.93 |
| 86803 | <1% | 43 | $630.07 | |
| 80143 | <1% | 17 | $550.14 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 25 | $429.56 |
| 80179 | <1% | 17 | $409.39 | |
| 87522 | Neg quan hep c or qual rna | <1% | 19 | $382.23 |
| 83605 | <1% | 53 | $335.32 | |
| 82043 | <1% | 75 | $334.65 | |
| 82570 | <1% | 75 | $299.35 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 14 | $230.53 |
| 84439 | <1% | 39 | $224.80 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 85 | $221.42 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 27 | $202.01 |
| 86702 | <1% | 14 | $144.77 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 12 | $134.64 |
| 87081 | <1% | 12 | $117.92 | |
| 90686 | <1% | 64 | $115.76 | |
| 86701 | <1% | 14 | $109.31 | |
| 82746 | <1% | 13 | $75.50 | |
| 81002 | <1% | 27 | $46.90 | |
| 82962 | <1% | 30 | $27.40 | |
| 81000 | <1% | 12 | $20.75 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 27 | $5.39 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 13 | $4.80 |
| A9270 | Non-covered item or service | 0% | 394 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEFURIO, ANTHONY (EXECUTIVE VICE PRESIDENT/CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.